Robert Kramer - 28 Feb 2022 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
President and CEO, Director
Signature
/s/ S. Scott Lieberman, Attorney-in-fact
Issuer symbol
EBS
Transactions as of
28 Feb 2022
Net transactions value
+$5,531,973
Form type
4
Filing time
02 Mar 2022, 18:25:49 UTC
Previous filing
25 Feb 2022
Next filing
10 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Award $0 +33,833 +21% $0.000000 193,102 01 Mar 2022 Direct F1
transaction EBS Common Stock Award $0 +55,582 +29% $0.000000 248,684 01 Mar 2022 Direct F2
transaction EBS Common Stock Tax liability $67,983 -1,715 -0.69% $39.64* 246,969 28 Feb 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EBS Employee Stock Options (Right to Buy) Award $5,599,955 +135,330 $41.38* 135,330 01 Mar 2022 Common Stock 135,330 $41.38 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
F2 Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.
F3 Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes.
F4 Vests in three equal installments beginning on the day prior to the anniversary date of the grant.